Sep 28, 2026 07:02AM
Sep 28, 2026 07:00AM
Aug 11, 2026 04:00PM
Jun 4, 2026 07:01AM
Jun 4, 2026 07:00AM
May 11, 2026 04:01PM
Mar 31, 2026 07:00AM AN2 Therapeutics starts phase 2 trial for lung infection treatment
Mar 31, 2026 07:00AM
Mar 17, 2026 04:00PM
Jan 12, 2026 07:06AM
Jan 12, 2026 07:00AM
Nov 12, 2025 04:01PM
Nov 10, 2025 07:00AM
Nov 10, 2025 07:00AM AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
Aug 12, 2025 04:01PM
Aug 12, 2025 07:02AM
Aug 12, 2025 07:00AM
Jul 23, 2025 07:00AM
Jul 23, 2025 07:00AM
Jun 30, 2025 07:02AM
Jun 30, 2025 07:00AM AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
May 13, 2025 04:01PM
May 1, 2025 04:00PM
May 1, 2025 04:00PM
Mar 26, 2025 04:06AM
Mar 26, 2025 01:46AM
Mar 25, 2025 04:00PM
Feb 24, 2025 07:03AM AN2 Therapeutics, Inc (ANTX) Provides Strategic Update for Phase 3 EBO-301 Trial
Feb 24, 2025 07:00AM
Feb 20, 2025 04:07AM
Feb 3, 2025 04:13AM
Jan 28, 2025 05:42AM
Nov 18, 2024 02:43AM
Nov 13, 2024 04:00PM
Oct 17, 2024 07:03AM AN2 Therapeutics (ANTX) Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis and Malaria
Oct 17, 2024 07:00AM
May 14, 2024 04:01PM
Apr 2, 2024 03:37AM
Mar 28, 2024 04:10PM
Feb 12, 2024 06:45AM
Feb 12, 2024 06:45AM
Nov 9, 2023 04:05PM AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
Oct 11, 2023 12:01AM
Sep 13, 2023 07:00AM
Aug 10, 2023 04:10PM
Jul 5, 2023 07:18PM
Mar 29, 2023 04:01PM
Mar 24, 2023 01:18AM
Nov 9, 2022 04:05PM AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
Aug 11, 2022 04:10PM

334,273 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All